Related Experiment Video
Updated: Jul 17, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
[Anti-interleukin-5 therapy for eosinophilic diseases]
D Simon1, L R Braathen, H-U Simon
1Klinik und Poliklinik für Dermatologie und Venerologie, Inselspital, Universität Bern, 3010 Bern. dagmar.simon@insel.ch
Summary
Blocking interleukin-5 (IL-5) with antibodies effectively reduces eosinophil counts and improves symptoms in certain eosinophilic diseases. However, its efficacy varies, necessitating further research to identify specific conditions where anti-IL-5 therapy is beneficial.
Area of Science:
- Immunology
- Allergy and Immunology
- Pathophysiology of Eosinophilic Disorders
Background:
- Elevated interleukin-5 (IL-5) levels are characteristic of several diseases involving eosinophilia.
- IL-5 is a key cytokine regulating eosinophil development, activation, and survival.
Purpose of the Study:
- To evaluate the therapeutic potential of neutralizing IL-5 through blocking antibodies in eosinophilic diseases.
- To assess the clinical efficacy of anti-IL-5 therapy across different eosinophilic conditions.
Main Methods:
- Administration of anti-IL-5 blocking antibodies in clinical trials.
- Monitoring peripheral blood eosinophil counts and clinical symptom improvement.
Main Results:
- Anti-IL-5 therapy led to a rapid reduction in peripheral blood eosinophil numbers.
- Significant symptom improvement was observed in lymphocytic hypereosinophilic syndromes, eosinophilic esophagitis, and chronic rhinitis with nasal polyposis.
- Moderate or no clinical effects were noted in patients with bronchial asthma or atopic eczema.
Conclusions:
- Neutralizing IL-5 is a promising strategy for treating specific eosinophilic diseases.
- The effectiveness of anti-IL-5 therapy is disease-dependent, highlighting the need for targeted application.
- Future research should focus on identifying biomarkers to predict patient response to anti-IL-5 treatments.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.